E
Epcoritamab
Availability of ACE Drug Guidance
Yes
Biologics Drug Information Overview
Yes
Post-marketing information
Patient Alert Card
Subsidy Information and Financing Scheme
Cancer Drug and Clinical Indication listed in the MediShield Life Outpatient Cancer Drug List
Active ingredient: Epcoritamab
General information
Subsidy Information and Financing Scheme
[MSHL] Epcoritamab Concentrate For Solution For Injection 4 mg/0.8 mL
For the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy.
[MSHL] Epcoritamab Solution For Injection 48 mg/0.8 mL
For the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy.
Drug Guidance for Subsidy
[NR] The Ministry of Health’s Drug Advisory Committee has not recommended epcoritamab for inclusion on the MOH List of Subsidised Drugs for treating relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. The decision for epcoritamab was based on the uncertainties surrounding its magnitude of clinical benefit, unfavourable cost-effectiveness compared with chemotherapy, and the unacceptable price-volume agreement proposed by the company.
Clinical indication, subsidy class and MediShield Life claim limit for epcoritamab are provided in the Annex.
Post Marketing Information
General Availability in Public Healthcare Institution
Note:
General availability information reflected is based on the Public Healthcare Institutions’ (PHI) formulary on what is commonly used for treating their patient population and may or may not be available for patients not under the care of that institution. It does not reflect the PHI’s actual inventory availability and is subjected to change. Please consult the Public Hospitals or Polyclinics for details on availability and supply restrictions/considerations. General availability is not tied to any brand unless otherwise stated.
Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration
Availability information
Formulation | Public Healthcare Institution |
|---|---|
Epkinly Concentrate For Solution For Injection 4 mg/0.8 mL |
|
Epkinly Solution For Injection 48 mg/0.8 mL |
|